These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15153172)

  • 1. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
    Kivitz AJ; Nayiager S; Schimansky T; Gimona A; Thurston HJ; Hawkey C
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1189-98. PubMed ID: 15153172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    Hawkey CC; Svoboda P; Fiedorowicz-Fabrycy IF; Nasonov EL; Pikhlak EG; Cousin M; Gitton X; Hoexter G
    J Rheumatol; 2004 Sep; 31(9):1804-10. PubMed ID: 15338504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
    Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
    Hawkey CJ; Farkouh M; Gitton X; Ehrsam E; Huels J; Richardson P
    Aliment Pharmacol Ther; 2004 Jul; 20(1):51-63. PubMed ID: 15225171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
    Hawkey CJ; Gitton X; Hoexter G; Richard D; Weinstein WM
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):57-66. PubMed ID: 16431306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
    Sikes DH; Agrawal NM; Zhao WW; Kent JD; Recker DP; Verburg KM
    Eur J Gastroenterol Hepatol; 2002 Oct; 14(10):1101-11. PubMed ID: 12362101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
    Cheung R; Cheng TT; Dong Y; Lin HY; Lai K; Lau CS; Feng H; Parsons B
    Int J Rheum Dis; 2010 May; 13(2):151-7. PubMed ID: 20536600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
    Bannwarth B; Berenbaum F
    Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
    MacDonald TM; Reginster JY; Littlejohn TW; Richard D; Lheritier K; Krammer G; Rebuli R
    J Hypertens; 2008 Aug; 26(8):1695-702. PubMed ID: 18622250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib.
    Ashcroft DM; Chapman SR; Clark WK; Millson DS
    Ann Pharmacother; 2001; 35(7-8):829-34. PubMed ID: 11485128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
    Whelton A; Lefkowith JL; West CR; Verburg KM
    Kidney Int; 2006 Oct; 70(8):1495-502. PubMed ID: 16941030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
    Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Wittenberg RH; Schell E; Krehan G; Maeumbaed R; Runge H; Schlüter P; Fashola TO; Thurston HJ; Burger KJ; Trechsel U
    Arthritis Res Ther; 2006; 8(2):R35. PubMed ID: 16469112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.